Cardiovascular
Cardiopulmonary Bypass
2
Pipeline Programs↗
11
Active Trials↗
10
Companies Involved↗
Cardiopulmonary Bypass is an early-stage landscape with 2 programs across 10 companies. The most active players are Novartis, CSL Behring, Grifols Therapeutics LLC.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Phase 1
No programs
Phase 2
No programs
Phase 3
No programs
Approved
No programs
Analysis
Trial Status
89
clinical trials
Completed56 · 63%
Unknown status10 · 11%
Terminated8 · 9%
Recruiting7 · 8%
Withdrawn3 · 3%
Not yet recruiting3 · 3%
Other2 · 2%
Clinical Trials
Trial Activity
89 trials
Prophylactic Methylprednisolone for Renal Protection in Cardiac Surgeries With Cardiopulmonary Bypass
Recruiting·—·Phase 1·NCT06917859·170 enrolled
Effect of Lithium Carbonate on Postoperative Sleep and Cognitive Function in Patients Undergoing Heart Valve Surgery With Cardiopulmonary Bypass
Recruiting·—·Phase 4·NCT05593627·62 enrolled
Individualized Dose of Fibrinogen Following Cardiopulmonary Bypass
Not yet recruiting·—·N/A·NCT07425600·150 enrolled
Use of Ketamine Prior to Cardiopulmonary Bypass in Children
Completed·—·Phase 2·NCT00556361·24 enrolled
Page 1 of 6
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)